Home
Categories
Ingredients
Analysis
Manufacturing
Finance
Regulatory
Drug Delivery
Research & Development
Sustainability
Pharma 5.0
Company News
Events
Directory
Search
Close search
Home
Company
Polyphor
Polyphor
Activities:
Research & Development
X
LinkedIn
Trending Articles
Innovation in generics: increased efficiency through peptide API synthesis expertise
Leading Swiss pharmaceutical company Bachem explains the benefits of converging LPPS in the manufacturing of gonadotropin-releasing hormone (GnRH) analogues
COVID-19 still a significant risk for the immunocompromised, study finds
AstraZeneca's INFORM study highlights the persistent danger of COVID-19 for the immunocompromised despite the vaccination scheme
US court lifts modified consent decree on Xellia’s Cleveland facility
The Modified Consent Decree imposed on Xellia's Cleveland facility in 2016 has been vacated, receiving a VAI
Lonza's AI-enabled small molecule development tool launches
The company's AI-enabled Route Scouting Service will optimise synthetic route identification when identifying novel APIs
Autoscribe Informatics’ new Australia office supports business growth
The company's move to West Lakes Adelaide expands its ability to service the Asia Pacific region in digitalising laboratory information
Upcoming event
ASGCT Annual Meeting 2024
7-11 May, 2024 | Meeting | Portland, OR
See all
Related Content
Research & Development
Polyphor and Wellcome Trust to develop novel antibiotics against multi-drug resistant Gram-negative pathogens
Final milestone reached ahead of schedule triggering payment of a CHF 0.97 million convertible loan amount
Research & Development
Kalina Scott appointed new CFO of Polyphor
Research & Development
New hope against antibiotic resistance: Outer-Membrane Protein Targeting Antibiotics
OMPTA platform could bring further new important therapies in the treatment of Gram-negative pathogens
Recruitment
Debra Barker appointed as new CMDO of Polyphor
Polyphor has announced the appointment of Dr Debra Barker, MD and MSc, to the role of Chief Medical and Development Officer (CMDO)
Research & Development
Polyphor appoints Michael Altorfer as Chief Executive
He replaces Jean-Pierre Obrecht, who will continue as a member of the Board of Directors
Research & Development
Roche signs licensing agreement with Polyphor to combat multi-drug resistant infections
Makes an upfront payment of CHF35m to Polyphor in deal that could be worth up to CHF500m
Research & Development
Polyphor signs MacroFinder collaboration with Boehringer Ingelheim
Will use technology to identify drug candidates addressing therapeutic targets chosen by BI
Subscribe now